Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics,
Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the
"
Company" or "
Claritas") today
announced the addition of Perenlei Enkhbaatar, MD, PhD, FAHA
as an independent member of the Company’s board of directors (the
“Board of Directors”), effective immediately.
Dr. Enkhbaatar is an internationally renowned
authority and leader on the biology and pathophysiology of nitric
oxide and acute lung injury, and his appointment to the Board of
Directors will further strengthen the Company position as a leader
in the field of nitric oxide therapeutics.
Nitric oxide was named molecule of the year by
Science magazine in 1992; over 130,000 peer reviewed articles have
been published on the nitric oxide; and nitric oxide was the
subject of a 1998 Nobel Prize in medicine.
“The addition of Dr. Enkhbaatar to the Company’s
Board enhances and strengthens our focus on nitric oxide
pharmaceuticals,” stated Robert Farrell, President and CEO. “We
previously announced the addition of Dr. Salvatore Cuzzocrea to our
Board. Both Dr. Enkhbaatar and Dr. Cuzzocrea are internationally
renowned authorities and leaders on the biology and pathophysiology
of nitric oxide. Drs. Enkhbaatar and Cuzzocrea will help guide the
Company’s development of R-107, our proprietary nitric
oxide-releasing compound that is being developed as a treatment for
coronavirus, COVID-19, and other viral infections. Dr. Enkhbaatar
will be a strong strategic resource for Claritas, and we look
forward to the contributions he will make.”
Nitric oxide is part of the body’s natural
defense system against viral infections. However, a viral infection
can spread more rapidly than the body can produce nitric oxide to
combat the infection. Claritas is developing R-107 to supplement
the body’s natural production of nitric oxide. Following
administration orally as a capsule, or nasally through use of a
nasal spray, or by injection, R-107 releases nitric oxide
systemically throughout the body.
The importance of R-107 for the treatment of,
and possibly also the prevention of, COVID-19 cannot be overstated.
Unlike vaccines, that may lose effectiveness as the virus mutates,
nitric oxide-releasing R-107 is expected to be a universal therapy
against all COVID-19 strains, including those that are
vaccine-resistant.
Dr. Enkhbaatar currently serves as
the Charles Robert Allen Professor and the Director of the
Translational Intensive Care Unit in the Department of
Anesthesiology at the University of Texas Galveston Medical
Branch.
Following his medical training at the University
of Saint Petersburg in Russia, Dr. Enkhbaatar served as a
Senior Lieutenant physician in the Mongolian Army. He went on to
receive his Ph.D. at Kumamoto University Graduate School of
Medical Sciences in Japan. He then undertook his post-doctoral
training in the Department of Anesthesiology, University of Texas
Medical Branch in Galveston, Texas, under the mentorship of the
late Professor Daniel Traber, the foremost authority over the last
fifty years on the pathophysiology of acute lung injury. Upon Dr.
Traber’s death, Dr. Enkhbaatar assumed the leadership of
the research unit in Galveston and has further expanded its
research prominence in the development of effective therapeutic
approaches with special emphasis on tissue regeneration and stem
cell biology.
For the past 25 years,
Dr. Enkhbaatar has played a leading role in the
elucidation of basic mechanisms of disease in acute lung injury and
acute respiratory distress syndrome secondary to pneumonia, sepsis,
toxic gas inhalation, and thermal injury associated with smoke
inhalation. He has been at the forefront of pioneering
therapeutic approaches to counter reactive oxidative and
nitrosative stress. In recognition of these advances in the medical
science of acute lung injury, Dr. Enkhbaatar has been
awarded numerous federal grants, including funding from the
National Institutes of Health, the American Heart Association, the
Department of Defense, Shriners of North America, and the Office of
Naval Research. His research advances have been presented at
international conferences and in the publication of more than three
hundred abstracts, one hundred and fifty-four original manuscripts
in leading peer-reviewed journals, and twelve book chapters.
In recognition of his contributions to the field
of cytokine storm induced acute lung injury,
Dr. Enkhbaatar has been selected to serve on the
Editorial Boards of leading journals in the fields of trauma and
acute lung injury, including Critical Care
Medicine, Shock, and Burn & Trauma, and has been
invited to join numerous professional societies, including the
Society of Critical Care Medicine, the American Burn Association,
the Shock Society, the American Thoracic Society, the American
Physiological Society, the American Heart Association, the Surgical
Infection Society, and the Royal Society of Medicine.
Dr. Enkhbaatar brings expert knowledge
of R-107 to Claritas, having carried out clinically relevant large
animal studies showing its treatment benefit in experimental models
of bacterial pneumonia, smoke inhalation and burn injury, and
chlorine inhalational lung injury. As a world authority on the
biological mechanisms of pulmonary damage in cytokine-storm induced
acute lung injury, Dr. Enkhbaatar is ideally positioned
to appreciate the underlying pathophysiology of COVID-19 disease
and to guide potential therapeutic approaches based on the
provision of nitric oxide via the clinical administration of
R-107.
Professor Salvatore Cuzzocrea, a member of the
Company’s Board of Directors, President of the University of
Messina and former President of the European Shock Society, has
read and approved the scientific disclosure in this news
release. Professor Cuzzocrea has deep expertise regarding the
medical use of nitric oxide and nitric oxide donors, and has
published more than 600 papers on nitric oxide. He has conducted
research and experiments with nitric oxide and nitric oxide donors
since 1994, and worked closely as an advisor with the Salzman Group
team that designed and invented R-107.
The Company is not making any express or implied
claims that its product has the ability to eliminate, cure, or
contain the Covid-19 (or SARS-2 Coronavirus) at this time.
About Claritas
PharmaceuticalsClaritas Pharmaceuticals, Inc. is a
clinical stage biopharmaceutical company focused on developing and
commercializing therapies for patients with significant unmet
medical needs. Claritas focuses on areas of unmet medical need, and
leverages its expertise to find solutions that will improve health
outcomes and dramatically improve people's lives.
- Website
Home: https://claritaspharma.com/
- News and
Insights: https://claritaspharma.com/news/
-
Investors: https://claritaspharma.com/investors
Cautionary StatementsNeither
TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
This press release may contain certain
forward-looking information and statements ("forward-looking
information") within the meaning of applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation in respect of its product candidate pipeline,
planned clinical trials, regulatory approval prospects,
intellectual property objectives, and other statements containing
the words "believes", "anticipates", "plans", "intends", "will",
"should", "expects", "continue", "estimate", "forecasts" and other
similar expressions. Readers are cautioned to not place undue
reliance on forward-looking information. Actual results and
developments may differ materially from those contemplated by these
statements depending on, among other things, the risk that future
clinical studies may not proceed as expected or may produce
unfavorable results. Claritas undertakes no obligation to comment
on analyses, expectations or statements made by third parties, its
securities, or financial or operating results (as applicable).
Although Claritas believes that the expectations reflected in
forward-looking information in this press release are reasonable,
such forward-looking information has been based on expectations,
factors and assumptions concerning future events which may prove to
be inaccurate and are subject to numerous risks and uncertainties,
certain of which are beyond Claritas’ control. The forward-looking
information contained in this press release is expressly qualified
by this cautionary statement and is made as of the date hereof.
Claritas disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise.
Contact InformationRobert
FarrellPresident, CEO(888) 861-2008info@claritaspharma.com
Kalytera Therapeutics (TSXV:KLY)
Historical Stock Chart
From Apr 2024 to May 2024
Kalytera Therapeutics (TSXV:KLY)
Historical Stock Chart
From May 2023 to May 2024